215 related articles for article (PubMed ID: 33275172)
1. BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes.
Peiffer L; Farahpour F; Sriram A; Spassova I; Hoffmann D; Kubat L; Stoitzner P; Gambichler T; Sucker A; Ugurel S; Schadendorf D; Becker JC
Cancer Immunol Immunother; 2021 Jun; 70(6):1635-1647. PubMed ID: 33275172
[TBL] [Abstract][Full Text] [Related]
2. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
3. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.
Wilmott JS; Long GV; Howle JR; Haydu LE; Sharma RN; Thompson JF; Kefford RF; Hersey P; Scolyer RA
Clin Cancer Res; 2012 Mar; 18(5):1386-94. PubMed ID: 22156613
[TBL] [Abstract][Full Text] [Related]
4. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
Nassar KW; Hintzsche JD; Bagby SM; Espinoza V; Langouët-Astrié C; Amato CM; Chimed TS; Fujita M; Robinson W; Tan AC; Schweppe RE
Mol Cancer Ther; 2021 Oct; 20(10):2049-2060. PubMed ID: 34376578
[TBL] [Abstract][Full Text] [Related]
5. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
Frederick DT; Piris A; Cogdill AP; Cooper ZA; Lezcano C; Ferrone CR; Mitra D; Boni A; Newton LP; Liu C; Peng W; Sullivan RJ; Lawrence DP; Hodi FS; Overwijk WW; Lizée G; Murphy GF; Hwu P; Flaherty KT; Fisher DE; Wargo JA
Clin Cancer Res; 2013 Mar; 19(5):1225-31. PubMed ID: 23307859
[TBL] [Abstract][Full Text] [Related]
6. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
Liu C; Peng W; Xu C; Lou Y; Zhang M; Wargo JA; Chen JQ; Li HS; Watowich SS; Yang Y; Tompers Frederick D; Cooper ZA; Mbofung RM; Whittington M; Flaherty KT; Woodman SE; Davies MA; Radvanyi LG; Overwijk WW; Lizée G; Hwu P
Clin Cancer Res; 2013 Jan; 19(2):393-403. PubMed ID: 23204132
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.
Lai X; Friedman A
BMC Syst Biol; 2017 Jul; 11(1):70. PubMed ID: 28724377
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
[TBL] [Abstract][Full Text] [Related]
9. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA
Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021
[TBL] [Abstract][Full Text] [Related]
10. Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.
Wang VE; Xue JY; Frederick DT; Cao Y; Lin E; Wilson C; Urisman A; Carbone DP; Flaherty KT; Bernards R; Lito P; Settleman J; McCormick F
Clin Cancer Res; 2019 Dec; 25(23):7202-7217. PubMed ID: 31515463
[TBL] [Abstract][Full Text] [Related]
11. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
12. Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma.
Lelliott EJ; Mangiola S; Ramsbottom KM; Zethoven M; Lim L; Lau PKH; Oliver AJ; Martelotto LG; Kirby L; Martin C; Patel RP; Slater A; Cullinane C; Papenfuss AT; Haynes NM; McArthur GA; Oliaro J; Sheppard KE
Cancer Immunol Res; 2021 Feb; 9(2):136-146. PubMed ID: 33303574
[TBL] [Abstract][Full Text] [Related]
13. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
14. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
15. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
[TBL] [Abstract][Full Text] [Related]
16. The density and spatial tissue distribution of CD8
Massi D; Rulli E; Cossa M; Valeri B; Rodolfo M; Merelli B; De Logu F; Nassini R; Del Vecchio M; Di Guardo L; De Penni R; Guida M; Sileni VC; Di Giacomo AM; Tucci M; Occelli M; Portelli F; Vallacchi V; Consoli F; Quaglino P; Queirolo P; Baroni G; Carnevale-Schianca F; Cattaneo L; Minisini A; Palmieri G; Rivoltini L; Mandalà M;
J Immunother Cancer; 2019 Nov; 7(1):308. PubMed ID: 31730502
[TBL] [Abstract][Full Text] [Related]
17. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
Drago JZ; Lawrence D; Livingstone E; Zimmer L; Chen T; Giobbie-Hurder A; Amann VC; Mangana J; Siano M; Zippelius A; Dummer R; Goldinger SM; Sullivan RJ
Melanoma Res; 2019 Feb; 29(1):65-69. PubMed ID: 30376465
[TBL] [Abstract][Full Text] [Related]
19. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
20. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
Boni A; Cogdill AP; Dang P; Udayakumar D; Njauw CN; Sloss CM; Ferrone CR; Flaherty KT; Lawrence DP; Fisher DE; Tsao H; Wargo JA
Cancer Res; 2010 Jul; 70(13):5213-9. PubMed ID: 20551059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]